Kumar Smiti, Chawla Garima, Bansal Arvind K
Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Nagar, Punjab, India.
Yakugaku Zasshi. 2008 Feb;128(2):281-9. doi: 10.1248/yakushi.128.281.
Crystallization in the presence of additives like surfactants and polymers is a relatively less explored area but is important for polymorphic screening of a compound during its developmental stage. Surfactants and polymers act by various mechanisms to influence either the growth or the nucleation phase, resulting in modification of either the polymorphic form or the crystal habit. The present study was aimed at understanding the crystallization behavior of the model drug mebendazole (MBZ) in the presence of an inert polymer polyvinyl pyrrolidone (PVP) and an anionic surfactant sodium lauryl sulphate (SLS). Crystals were generated by the antisolvent approach using the surfactant and polymer solutions in water as the antisolvents. Change in habit from needles to plates took place as a result of modification of the crystallization process in the presence of additive molecules. This was confirmed by quantification of these additives using specific analytical methods, which revealed their presence in small amounts in the final product (0.02, 0.15, and 0.24% w/w SLS in crystals generated using 0.5, 1.0, and 2.0% SLS, respectively, and 0.94, and 1.24% w/w PVP K30 and PVP K90, respectively). Their presence in the crystals led to modification in the dissolution of the drug. SLS improved the extent of dissolution while PVP had a negative impact and led to reduction in the amount of MBZ released even below that of the pure drug. The study highlights the influence of polymeric and surfactant additives on the crystallization process leading to modified performance.
在表面活性剂和聚合物等添加剂存在的情况下进行结晶是一个相对较少被探索的领域,但对于化合物在其研发阶段的多晶型筛选很重要。表面活性剂和聚合物通过各种机制影响生长或成核阶段,从而导致多晶型形式或晶体习性的改变。本研究旨在了解模型药物甲苯达唑(MBZ)在惰性聚合物聚乙烯吡咯烷酮(PVP)和阴离子表面活性剂十二烷基硫酸钠(SLS)存在下的结晶行为。通过反溶剂法生成晶体,使用水中的表面活性剂和聚合物溶液作为反溶剂。由于添加剂分子存在下结晶过程的改变,晶体习性从针状变为片状。使用特定分析方法对这些添加剂进行定量证实了这一点,结果显示它们在最终产物中的含量较少(在分别使用0.5%、1.0%和2.0% SLS生成的晶体中,SLS的含量分别为0.02%、0.15%和0.24% w/w,PVP K30和PVP K90的含量分别为0.94%和1.24% w/w)。它们在晶体中的存在导致药物溶解发生改变。SLS提高了溶解程度,而PVP则产生负面影响,导致MBZ释放量减少,甚至低于纯药物的释放量。该研究突出了聚合物和表面活性剂添加剂对结晶过程的影响,进而导致性能改变。